Medical Advocates
Nevirapine (Viramune)
 
Journal Citations

General Reports
Animal Studies
Formulations/Dosing           
Safety/Tolerability
 Pharmacokinetics      
Drug/Drug Interactions
 Resistance
Viral Dynamics
Diagnostics
 Adverse Events
 Efficacy
 Adolescent/Adult Treatment
Therapeutic Strategies 
 Special Populations 
Investigator Interviews





 
NVP Main Page  Main New/Newsworthy

Home Page

  

 

  
Last Update:  October 04, 2008
 Perinatal Journal Data are in the Perinatal Data Page
Pediatric Journal Data are in the Pediatric Data Page
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
 
Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells.
 Stefanidis K, Loutradis D, Vassiliou LV, et al 
Gynecol Oncol. 2008 Sep 24.
 Abstract
 
Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity.
 Streck EL, Scaini G, Rezin GT, et al 
Metab Brain Dis. 2008 Sep 24.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and
co-medication.
 Stöhr W, Back D, Dunn D, et al
Antivir Ther. 2008;13(5):675-85.
 Abstract
 
Synthesis and Characterization of DNA Adducts from the HIV Reverse Transcriptase Inhibitor Nevirapine.
 Antunes AM, Duarte MP, Santos PP, et al 
Chem Res Toxicol. 2008 Jul 3
 Abstract
 
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma
concentrations in HIV-infected patients.
 Wyen C, Hendra H, Vogel M, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract
 
Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of
residues L100, V106, and Y181 in the presence of nevirapine and efavirenz.
 Kroeger Smith MB, Rader LH, et al   
 Bioorg Med Chem Lett. 2007 Dec 23
Abstract
 
Synthesis and anti-HIV activity of nevirapine prodrugs.
 Sriram D, Yogeeswari P, Kishore MR.
 Pharmazie. 2006 Nov;61(11):895-7
 Abstract
 
Enzyme Inducers Reduce Elimination Half-Life After a Single Dose of Nevirapine in Healthy
Women.
 L'homme RF, Dijkema T, van der Ven AJ, Burger DM
J Acquir Immune Defic Syndr. 2006 Aug 24;
 Abstract
 
The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz
in the treatment of patients with a chronic HIV-I infection
 van Leth F, Lange JM. 
Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1719-22
 Abstract

Nevirapine derivatives with broad-spectrum chemotherapeutic properties for the effective
treatment of HIV/AIDS.
 Sriram D, Srichakravarthy N, Bal TR, Yogeeswari P. 
Biomed Pharmacother. 2005 Sep;59(8):456-9.
Abstract
Animal Studies
 
  RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced
hepatotoxicity.
 Walubo A, Barr S, Abraham AM.
Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):423-31.
 Abstract
Formulations/Dosing
 
 
Once- or twice-daily dosing of nevirapine in HIV-infected adults:
a population pharmacokinetics approach.
Moltó J, Valle M, Miranda C ,et al
J Antimicrob Chemother. 2008 Jun 30.
Abstract

Once-daily dosing of nevirapine in HAART.
Clotet B.
 J Antimicrob Chemother. 2007 Nov 14;
Abstract

Bioequivalence study of two nevirapine tablet formulations in human immunodeficiency
virus-infected patients
Tarinas A, Tápanes RD, González D, et al
Farm Hosp. 2007 Jun;31(3):165-168.
 Abstract
Safety/Tolerability
 
 
A WEEK IN REVIEW FEATURED REPORT
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with z
idovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
 Dart Trial Team 
Trop Med Int Health. 2008 Jan;13(1):6-16.
 Abstract
Pharmacokinetics
           
 
A WEEK-IN-REVIEW FEATURED REPORT
 Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
 Cooper C, van Heeswijk R.
HIV Med. 2007 Jan;8(1):1-7.
 Abstract
 
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant
women and women in late pregnancy.
 von Hentig N, Carlebach A, Gute P, et al
Br J Clin Pharmacol. 2006 Nov;62(5):552-9.
Abstract
 
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency
virus-infected individuals.
 Almond LM, Edirisinghe D, Dalton M, et al 
Clin Pharmacol Ther. 2005 Aug;78(2):132-42
 Abstract
 
Short communication: changes in nevirapine plasma concentrations over time and its
relationship with liver enzyme elevations.
De Requena DG, Jimenez-Nacher I, Soriano V.
AIDS Res Hum Retroviruses. 2005 Jun;21(6):555-9.
Abstract
 
Race Is Not Associated with Nevirapine Pharmacokinetics.
 De Maat MM, Nellen JF, Huitema AD   
Ther Drug Monit. 2004 Aug;26(4):456-458.
 Abstract
 
No relationship between high nevirapine plasma concentration and hepatotoxicity
in HIV-1-infected patients naive of antiretroviral treatment or switched from protease
inhibitors.
 Dailly E, Billaud E, Reliquet V 
Eur J Clin Pharmacol. 2004 May 20
 Abstract

Exposure of normal and transformed cells to nevirapine, a reverse transcriptase
inhibitor, reduces cell growth and promotes differentiation.
Mangiacasale R, Pittoggi C, Sciamanna I, et al.
Oncogene 2003 May 8;22(18):2750-61
 Abstract

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected
individuals.
De Maat MM, Huitema AD, Mulder JW, et al.
Br J Clin Pharmacol 2002 Oct;54(4):378-85
 Abstract

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected
individuals.
De Maat MM, Huitema AD,Mulder JW, et al.
Br J Clin Pharmacol 2002 May;53(5):552P
 Abstract

Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal  plasma.
van Praag RM, Repping S, de Vries JW, et al.
Antimicrob Agents Chemother 2001Oct;45(10):2902-2907
 Abstract

FULL-TEXT ARTICLE
 Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human
immunodeficiency virus-infected patients. The National Institute of Allergy and
Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Zhou XJ, Sheiner LB, D'Aquila RT, et al  
 Antimicrob Agents Chemother 1999
Paper

 		 
Viral Dynamics
 
 
Low Trough Plasma Concentrations of Nevirapine Associated with Virologic
Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors (April).
 Duong M, Buisson M, Peytavin G, et al  
Ann Pharmacother. 2005 Feb 15;
 Abstract
 
Predictors of virologic failure and resistance in HIV-infected patients treated with
nevirapine- or efavirenz-based antiretroviral therapy.
 Parienti JJ, Massari V, Descamps D, et al
Clin Infect Dis. 2004 May 1;38(9):1311-6.
 Abstract
 
Virologic and Immunologic Response to Regimens Containing Nevirapine or
Efavirenz  in Combination with 2 Nucleoside Analogues in the Italian Cohort Naive
Antiretrovirals (I.Co.N.A. Study)  
Cozzi-Lepri A, Phillips AN, Monforte Ad A, et al.
J Infect Dis 2002 Apr 15;185(8):1062-1069
 Abstract
 
Mechanism of Virologic Failure After Substitution of a Protease Inhibitor by
Nevirapine in Patients With Suppressed Plasma HIV-1 RNA.
Masquelier B, Neau D, Chene G, et al.
J Acquir Immune Defic Syndr 2001 Dec 1;28(4):309-12 
 Abstract
 
Resistance
 
 
Bayesian network analyses of resistance pathways against efavirenz and nevirapine.
 Deforche K, Camacho RJ, Grossman Z, et al   
AIDS. 2008 Oct 18;22(16):2107-15.
 Abstract
 
Comparison of genotypic resistance profiles and virological response between patients
starting nevirapine and efavirenz in EuroSIDA.
 Bannister WP, Ruiz L, Cozzi-Lepri A, et al  
AIDS. 2008 Jan 30;22(3):367-76
 Abstract
 
FULL TEXT ARTICLE
 N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine
and Nevirapine Resistance.
 Yap SH, Sheen CW, Fahey J, et al 
PLoS Med. 2007 Dec 1;4(12):e335
Abstract
 
Short Communication: HIV Type 1 Variants with Nevirapine Resistance Mutations Are Rarely
Detected in Antiretroviral Drug-Naive African Women with Subtypes A, C, and D.
 Church JD, Hudelson SE, Guay LA, et al 
AIDS Res Hum Retroviruses. 2007 Jun;23(6):764-8.
 Abstract
 
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in
HIV-infectedpatients in Uganda.
 Penzak S, Kabuye G, Mugyenyi P, et al 
HIV Med. 2007 Mar;8(2):86-91.
 Abstract
 
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with
nevirapine, efavirenz or abacavir.
 de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS. 2005 Sep 2;19(13):1385-1391.
Abstract
 
Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to
nevirapine through point mutations.
 He X, Mei Y, Xiang Y, et al 
Proteins. 2005 Aug 19;
Abstract
 
Novel patterns of nevirapine resistance-associated mutations of human
immunodeficiency virus type 1 in treatment-naive patients.
 Hachiya A, Gatanaga H, Kodama E, et al 
Virology. 2004 Oct 1;327(2):215-24.
Abstract
 
Competitive fitness of nevirapine-resistant human immunodeficiency virus type
1 mutants.
 Collins JA, Thompson MG, Paintsil E, et al 
J Virol. 2004 Jan;78(2):603-11.
 Abstract

FULL-TEXT  PDF ARTICLE
 Nevirapine resistance mutation at codon 181 of the  HIV-1 reverse transcriptase
confers Stavudine resistance by increasing nucleotide substrate discrimination 
and phosphorolytic activity
 Blanca G, Baldanti F, Paolucci S, et al.
J Biol Chem 2003 Feb 24;
 PDF Paper

 Patterns of resistance mutations selected by treatment of human immunodeficiency  
virus type 1infection with zidovudine, didanosine, and nevirapine. 
 Hanna GJ, Johnson VA, Kuritzkes DR et al.                          
Journal of Infectious Disease 2000; 181(3): 904-911.
 Abstract

Resistance profile and cross-resistance of HIV-1 among patients failing a non-
nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C, Rohban R, Simon A. et al.  
 J Med Virol 2001  Nov;65(3):445-8
Abstract

Novel deletion of hiv type 1 reverse transcriptase residue 69 conferring selective
high-level resistance to nevirapine.
 Suzuki K, Kaufmann GR, Mukaide M, et al.
AIDS Res Hum Retroviruses 2001 Sep;17(13):1293-6
 Abstract

 		 
Diagnostics/Monitoring
 
 
Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine
concentration in human plasma by MALDI-TOF/TOF.
 Notari S, Mancone C, Alonzi T, et al    
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jan 16
Abstract
 
An immunochromatographic strip test for the rapid detection of nevirapine in plasma samples of
HIV-infected patients.
 Cressey TR, Nangola S, Tawon Y, et al 
Antimicrob Agents Chemother. 2007 Jul 2
 Abstract
 
A simple and rapid liquid chromatography method for simultaneous determination of
zidovudine and nevirapine  in plasma.
Ramachandran G, Hemanthkumar AK, Kumaraswami V, Swaminathan S.
J tChromatogr B Analyt Technol Biomed Life Sci. 2006 Jun 30;
 Abstract
 
Detection of nevirapine in plasma using thin-layer chromatography.
 Dubuisson JG, King JR, Stringer JS, et al
 J Acquir Immune Defic Syndr. 2004 Feb 1; 35(2): 155-7.
 Abstract

An LC-MS-MS method for the determination of nevirapine, a non-nucleoside
reverse transcriptase inhibitor, in human plasma.
 Chi J, Jayewardene AL, Stone JA, Aweeka FT.
 Pharm Biomed Anal 2003 Apr 1;31(5):953-99
 Abstract

  
Efficacy
       
General Reports
 
 
Plasma Nevirapine Levels and 24-Week Efficacy in HIV-Infected Patients Receiving
Nevirapine-Based Highly Active Antiretroviral Therapy with or without Rifampicin.
 Manosuthi W, Sungkanuparph S, Thakkinstian A, et al
Clin Infect Dis. 2006 Jul 15;43(2):253-5
 Abstract
 
Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected
Patients.
 Bonjoch A, Paredes R, Domingo P, et al  
AIDS Res Hum Retroviruses. 2006 Apr;22(4):321-9.
Abstract

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety
of nevirapine or efavirenz-based first-line HAART.
 van Leth F, Andrews S, Grinsztejn B, Wilkins E
AIDS. 2005 Mar 25;19(5):463-471
 Abstract

NVP vs EFV
 
 
Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).
 Harmann M, Witte S, Brust J, et al
Int J STD AIDS. 2005 Jun;16(6):404-9.
Abstract
 
Plasma HIV-1 RNA Decline Within the First Two Weeks of Treatment Is
Comparable for Nevirapine, Efavirenz, or Both Drugs Combined and Is Not
Predictive of Long-Term Virologic Efficacy: A 2NN Substudy.
 van Leth F, Huisamen CB, Badaro R, et al 
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):296-300.
 Abstract
 
Efavirenz Versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label
Observational Study.
 Manfredi R, Calza L, Chiodo F. 
J Acquir Immune Defic Syndr. 2004 Mar 15;35(5):492-502.
 Abstract

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in
antiretroviral-naive patients with advanced HIV infection.
 Manosuthi W, Sungkanuparph S, Vibhagool A, et al
HIV Med. 2004 Mar;5(2):105-9.
Abstract
 

  
Generic
 
  Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based
generic highly active antiretroviral therapy in South India.
Saghayam S, Kumarasamy N, Cecelia AJ, et al
 Clin Infect Dis. 2007 Jan 15;44(2):295-300.
Abstract
Special Populations
 
Hemophiliacs
 
  Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia.
 Martorell M, Lopez RM, Ribera E
Enferm Infecc Microbiol Clin. 2005 Jun;23(6):349-5
 Abstract
Investigator Interviews
       
  José M. Gatell, MD, PhD
 September 25, 2003

NVP Main Page  Main New/Newsworthy

Home Page

  

 

  

Nevirapine Journal Data